In Vivo CAR-T Development Service with LNP-mRNA Technology

The Significance of In Vivo IVT mRNA-based CAR-T Engineering

In vitro transcribed mRNA CAR-T (IVT mRNA CAR T) cells act as a safe tumor therapy capable of addressing off-target tumor toxicity, in which T cells are briefly reprogrammed with mRNA encoding chimeric membrane antigen receptor proteins to combat TSA or TAA. In addition, IVT-mRNA CAR-T reduces side effects associated with off-target tumor toxicity due to mRNA instability. Currently, with the development of in situ cell engineering technology, in vivo IVT mRNA-based CAR-T engineering has been gradually developed for cancer immunotherapy.

Fig.1 IVT mRNA CAR-T therapy strategy. (Soundara Rajan, 2020)

Creative Biolabs' In Vivo CAR-T Development with LNP-mRNA Technology

Creative Biolabs provides an end-to-end solution for generating potent CAR-T cells directly within the body using optimized mRNA and next-generation lipid nanoparticle systems. This service enables clients to bypass complex ex vivo manufacturing, reduce timelines, and achieve controlled, transient CAR expression ideal for early-stage evaluation, mechanistic studies, and preclinical programs.

Our platforms support mRNA construct design, LNP optimization, immune activation assessment, and preclinical evaluation, enabling rapid, programmable CAR expression directly within the body. With advanced in vivo modeling, delivery-route optimization, and robust analytical capabilities, we provide an integrated framework that streamlines concept-to-preclinical workflows. Our team ensures flexibility, scalability, and scientific rigor, empowering clients to accelerate the development of next-generation in vivo CAR-T therapeutics.

Discover How We Can Help - Request a Consultation

Fig.2 IVT mRNA transported by polymeric nanoparticles programming T cells in situ. (Parayath,2020)

Technology Platform

Creative Biolabs' Workflow

The required starting materials include target antigen details and CAR construct outline, the intended administration route and species model for in vivo testing, and specific project objectives regarding activation profile and persistence expectations.

Workflow of In Vivo IVT mRNA-based CAR-T Cell Engineering. (Creative Biolabs Original)

Our Highlight Features

Representative Data

IVT mRNA CAR-T Cells Targeting Solid Malignancies

Summary: The study evaluated the safety and efficacy of adoptive cell therapy with IVT mRNA mesothelin-specific CAR-T cells in 6 patients with chemotherapy-refractory metastatic PDAC. After infusion, transient CAR expression was identified in patients' blood, leading to the proliferation of new immunoglobulin G proteins. The findings support the anticancer effect of mesothelin-specific IVT mRNA CAR-T Cells.

IVT mRNA CAR-T Cells Targeting Hematologic Malignancies

Summary: The study through the purification of mRNA encoding CAR to generate robust CAR-T cells. And in vivo investigations employing a leukemia mouse model found that T cells electroporated with pure mRNAs, regardless of nucleoside alteration, achieved the most effective 100-fold decrease of leukemic load.

If you want to learn more details about our in vivo IVT mRNA-based CAR-T engineering service, please don’t hesitate to contact us.

Frequently Asked Questions

Why Choose Us

Creative Biolabs provides a comprehensive suite of technology platforms enabling rapid, flexible, and scalable development of next-generation in vivo CAR-T therapeutics using LNP-formulated mRNA. Our services support every stage, from construct design to in vivo functional assessment, ensuring an efficient pathway toward translational success. Contact Our Team for More Information and to Discuss Your Project.

References

1. Soundara Rajan, T.; et al. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Int J Mol Sci. 2020, 21(18): 6514.
2. Parayath, N.N.; et al. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020, 11(1): 6080.
3. Beatty, G.L.; et al. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology. 2018, 155(1): 29-32.
4. Foster, J.B.; et al. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response. Hum Gene Ther. 2019, 30(2): 168-178.